1-(2,5-bis-trifluoromethyl-phenyl)-2-bromo-ethanone | 545410-49-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2,5-bis-trifluoromethyl-phenyl)-2-bromo-ethanone
• 英文别名: 2-bromo-1-[(2,5-bis-trifluoromethyl)phenyl]-ethanone；1-bromomethylcarbonyl-2,5-bistrifluoromethylbenzene；1-[2,5-bis(trifluoromethyl)phenyl]-2-bromoethanone
• CAS: 545410-49-9
• 化学式: C₁₀H₅BrF₆O
• 分子量: 335.044
• InChiKey: ZASNGXUKKCBWSY-UHFFFAOYSA-N

物化性质

• 沸点：
  254.7±40.0 °C(Predicted)
• 密度：
  1.665±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-(2,5-bis-trifluoromethyl-phenyl)-2-bromo-ethanone 生成 (R)-2-[5-(2,5-bis-trifluoromethyl-phenyl)-3-cyclohexylcarbamoyl-2-methyl-pyrrol-1-ylmethyl]-pyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Heterocyclic cannabinoid receptor antagonists

  摘要：

  本发明涉及公式I的化合物及其药用盐。这些化合物可用于治疗和/或预防与CB1受体调节相关的疾病。

  公开号：

  US20050250769A1
• 作为产物：
  描述：

  2,5-双(三氟甲基)苯甲酰氯 在 三丁基膦 、 溴 、 溶剂黄146 作用下， 生成 1-(2,5-bis-trifluoromethyl-phenyl)-2-bromo-ethanone
  参考文献：
  名称：

  N -[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F 1 F 0 ATP hydrolase

  摘要：

  A series of substituted guanidine derivatives were prepared and evaluated as potent and selective inhibitors of mitochondrial F1F0 ATP hydrolase. The initial thiourethane derived lead molecules possessed intriguing in vitro pharmacological profiles, though contained moieties considered non-drug-like. Analogue synthesis efforts led to compounds with maintained potency and superior physical properties. Small molecules in this series which potently and selectivity inhibit ATP hydrolase and not ATP synthase may have utility as cardioprotective agents. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.077

文献信息

• [EN] NOVEL CB 1 RECEPTOUR INVERSE AGONISTS<br/>[FR] NOUVEAUX AGONISTES INVERSES DU RECEPTEUR CB 1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004060870A1

  公开（公告）日：2004-07-22

  The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment . and/or prophylaxis of diseases which are associated with the modulation of CB 1 receptors.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、R6、m和X如描述和索赔中定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与CB1受体调节相关的疾病。
• (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
  申请人：——

  公开号：US20040039033A1

  公开（公告）日：2004-02-26

  Compounds having the formula (I), and pharmaceutically acceptable salts thereof, 1 are useful for modulating mitochondrial F 1 F 0 ATPase activity and treating ischemic conditions including myocardial infarction, congestive heart failure, and cardiac arrhythmias.

  具有化学式（I）的化合物及其药用盐对调节线粒体F1F0ATP酶活性和治疗包括心肌梗死、充血性心力衰竭和心律失常在内的缺血性疾病具有用处。
• [EN] PROCESS FOR PRODUCING TRIFLUOROMETHYL-SUBSTITUTED 2-ALKOXYACETOPHENONE DERIVATIVES<br/>[FR] PROCEDE DE PRODUCTION DE DERIVES DE 2-ALCOXYACETOPHENONE TRIFLUOROMETHYLE-SUBSTITUEE
  申请人：CENTRAL GLASS CO LTD

  公开号：WO2004014887A1

  公开（公告）日：2004-02-19

  A process for producing a brominated acetal (represented by the formula 3) includes (a) brominating a trifluoromethyl-substituted acetophenone by Br2 in the presence of an alkylene diol. It is optional to produce a trifluoromethyl-substituted 2-alkoxyacetophenone derivative (represented by the formula 9) by (b) reacting the brominated acetal with a metal alkoxide, thereby converting the brominated acetal into an ether; and (c) hydrolyzing the ether in the presence of an acid catalyst to remove an acetal group from the ether, thereby producing the 2-alkoxyacetophenone derivative. Alternatively, the 2-alkoxyacetophenone can be produced by (a) reacting a trifluoromethyl-substituted phenacyl halide with an acetalization agent, thereby converting the phenacyl halide into an acetal; (b) reacting the acetal with a metal alkoxide, thereby converting the acetal into an ether; and (c) hydrolyzing the ether in the presence of an acid catalyst to remove the acetal group from the ether.

  生产溴代缩醛（化学式3）的过程包括：（a）在烷基二醇存在下，用Br2对三氟甲基取代的乙酰苯甲酮进行溴化。可以通过以下步骤制备三氟甲基取代的2-烷氧基乙酰苯甲酮衍生物（化学式9）：（b）将溴代缩醛与金属烷氧化物反应，将溴代缩醛转化为醚；（c）在酸催化剂存在下水解醚，从而从醚中去除缩醛基，从而制备2-烷氧基乙酰苯甲酮衍生物。或者，可以通过以下步骤制备2-烷氧基乙酰苯甲酮：（a）将三氟甲基取代的苯甲酰卤与缩醛化试剂反应，将苯甲酰卤转化为缩醛；（b）将缩醛与金属烷氧化物反应，将缩醛转化为醚；（c）在酸催化剂存在下水解醚，从而从醚中去除缩醛基。
• Novel CB 1 receptor inverse agonists
  申请人：——

  公开号：US20040167129A1

  公开（公告）日：2004-08-26

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

  本发明涉及式（I）1的化合物，其中R1、R2、R3、R4、R5、R6、m和X如描述和权利要求中所定义，并且其制药可接受的盐。这些化合物对于治疗和/或预防与CB1受体调节相关的疾病是有用的。
• CB 1 receptor inverse agonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US07294644B2

  公开（公告）日：2007-11-13

  The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

  本发明涉及式(I)的化合物，其中R1，R2，R3，R4，R5，R6，m和X如描述和权利要求中所定义，并且其药学上可接受的盐。该化合物可用于治疗和/或预防与CB1受体调节相关的疾病。